A cost analysis of the prostaglandin analogs

Optometry

Volumn 73, Issue 10, 2002, Pages 614-619

  Mick, Andrew B ^a,b,c   Gonzalez, Serafin ^a   Dunbar, Mark T ^a   McSoley, John J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bimatoprost; Cost analysis; Drop size; Latanoprost; Percent overfill; Prostaglandin analogs; Travoprost; Unoprostone

Indexed keywords

ANTIHYPERTENSIVE AGENT; EYE DROPS; PROSTAGLANDIN F;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GLAUCOMA; HUMAN;

ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC;

EID: 0036780884     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Void SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma 2000;9:150-3.
2. Sherwood M, Brandt J. Six-month comparison of bimatoprost once daily and twice daily with timolol twice daily in patients with elevated interocular pressure. Surv Ophthalmol 2001;45(suppl. 4):s361-s368.
3. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once and twice daily bimatoprost with twice daily timolol in patients with elevated IOP. Ophthalmology 2001;108:1023-32.
4. Netland PA, Landry T, Sullivan K, et al. Travaprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84.
5. Aung T, Wong HT, Yip CC, et al. Comparison of the intraocular pressure lowering affect of latanoprost and timolol in patients with chronic angle closure glaucoma. Ophthalmology 2000;107:1178-83.
6. Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. Am J Ophthalmol 2002;133:1-10.
7. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3-month, randomized study. Br J Ophthalmol 2000;84:579-82.
8. Einarson TR. Kulin NA, Tingey D, et al. Meta-analysis of the effect of latanoprost and brimonidine on interocular pressure in the treatment of glaucoma. Clin Ther 2000;22:1502-15.
9. Susanna R Jr, Giampani J Jr., Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open angle glaucoma or ocular hypertension. Ophthalmology 2001;108:259-63.
10. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open angle glaucoma. Am J Ophthalmol 2001;132(4):485-9.
11. Aung T, Chew PT, Yip CC, et al. A randomized double masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open angle glaucoma and ocular hypertension. Am J Ophthalmol 2001;131:636-42.
12. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. International travapost study group. J Glaucoma 2001;10:414-22.
13. Stewart WC, Dubiner HB, Mundorf TK. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open angle glaucoma. Am J Ophthalmol 1999;127:142-7.
14. Velde TM, Kaiser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. Arch Intern Med 1983;143:1627.
15. Wistrand PJ, Stjernschantz J, Olsson K. The Incidence and time course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(suppl 2):s129-s138.
16. Wand M. Latanoprost and hyperpigmentation of eye-lashes. Arch Ophthalmol 1997;115:1206-8.
17. Warwar RE, Bullock JD. Latanoprost induced uveitis. Surv Ophthalmol 1999;43:466-8.
18. Miyake K, Ota I, Maekubo K. Latanoprost accelerates disruption of blood aqueous barrior and incidence of angiographic cystoid macular edema in early post operative pseudophakias. Arch Ophthalmol 1999;117:34-40.
19. Furuichi M, Chiba T, Abe K, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma 2001;10:233-6.
20. Lima MC, Paranhos A Jr, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma 2000;9:317-21.
21. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002; 133:393-7.
22. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relationship? Curr Opin Ophthalmol 2000;11:94-100.
23. Ball SF, Schneider E. Cost of beta-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol 1992;110:654-7.
24. Lederer CM, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthalmol 1986;101:691-4.
25. Mishima S, Gasset A, Klyce SD Jr, et al. Determination of tear volume and tear flow. Invest Ophthalmol 1966; 5:264-76.
26. Fiscella RG, Geller JL, Leanna GL, et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999;128:426-33.
27. Schwartz JS, Christensen RE, Lee DA. Comparison of timolol maleate and levobunolol: Doses and volume per bottle. Arch Ophthalmol 1989;107:17.
28. Fiscella RG. Cost of glaucoma medications. Am J Health Syst Pharm 1998;55:272-5.
29. Stewart WS, Sine C, Cate E, et al. Daily cost of beta-adrenergic blocker therapy. Arch Ophthalmol 1997; 115:853-6.
30. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21.
31. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(suppl. 4):353-60.